Apogee Therapeutics Inc. (APGE)
Apogee Therapeutics Statistics
Share Statistics
Apogee Therapeutics has 59.5M shares outstanding. The number of shares has increased by 1.79% in one year.
| Shares Outstanding | 59.5M |
| Shares Change (YoY) | 1.79% |
| Shares Change (QoQ) | 1.69% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 47.76M |
| Failed to Deliver (FTD) Shares | 2.59K |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 8.5M, so 14.53% of the outstanding shares have been sold short.
| Short Interest | 8.5M |
| Short % of Shares Out | 14.53% |
| Short % of Float | 18.02% |
| Short Ratio (days to cover) | 18.7 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -9.87. Apogee Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -9.87 |
| PS Ratio | 0 |
| Forward PS | 8.5 |
| PB Ratio | 3.49 |
| P/FCF Ratio | -14.51 |
| PEG Ratio | 0 |
Enterprise Valuation
Apogee Therapeutics has an Enterprise Value (EV) of 2.37B.
| EV / Sales | 0 |
| EV / EBITDA | -10.93 |
| EV / EBIT | -13.85 |
| EV / FCF | -13.75 |
Financial Position
The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 18.55 |
| Quick Ratio | 18.55 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 0% and Return on Invested Capital is 0%.
| Return on Equity | 0% |
| Return on Assets | 0% |
| Return on Invested Capital | 0% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 196 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -18K |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by -39.74% in the last 52 weeks. The beta is 1.73, so Apogee Therapeutics's price volatility has been higher than the market average.
| Beta | 1.73 |
| 52-Week Price Change | -39.74% |
| 50-Day Moving Average | 36.73 |
| 200-Day Moving Average | 45.39 |
| Relative Strength Index (RSI) | 39.48 |
| Average Volume (20 Days) | 686.15K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -216.87M |
| Net Income | 0 |
| EBITDA | -216.87M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 141.79M in cash and 11.83M in debt, giving a net cash position of 129.96M.
| Cash & Cash Equivalents | 141.79M |
| Total Debt | 11.83M |
| Net Cash | 129.96M |
| Retained Earnings | -305.92M |
| Total Assets | 753.95M |
| Working Capital | 501.15M |
Cash Flow
In the last 12 months, operating cash flow was -171.17M and capital expenditures -1.15M, giving a free cash flow of -172.33M.
| Operating Cash Flow | -171.17M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | -172.33M |
| FCF Per Share | -3.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -6.89% |
Analyst Forecast
The average price target for APGE is $89.5, which is 181.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $89.5 |
| Price Target Difference | 181.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 30.32 |
| Piotroski F-Score | 1 |